Strategic Alliance Agreements (Details) (USD $)	1 Months Ended	3 Months Ended	8 Months Ended	12 Months Ended					1 Months Ended			0 Months Ended	1 Months Ended	3 Months Ended	1 Months Ended
	Apr. 20, 2011	Jun. 30, 2011	Dec. 31, 2003	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2007	Dec. 31, 2004	Apr. 20, 2011 Sales of less than ten million [Member]	Apr. 20, 2011 Sales of ten to twenty million [Member]	Apr. 20, 2011 Sales in excess of twenty million [Member]	Apr. 20, 2011 Actient Pharmaceuticals, LLC [Member]	Apr. 20, 2011 Actient Pharmaceuticals, LLC [Member]	Jun. 30, 2011 Actient Pharmaceuticals, LLC [Member]	Apr. 20, 2011 Actient Pharmaceuticals, LLC [Member] Sales of less than ten million [Member]	Apr. 20, 2011 Actient Pharmaceuticals, LLC [Member] Sales of ten to twenty million [Member]	Apr. 20, 2011 Actient Pharmaceuticals, LLC [Member] Sales in excess of twenty million [Member]	Apr. 20, 2011 Actient Pharmaceuticals, LLC [Member] Royalty payments, after ten years from closing [Member]	Apr. 20, 2011 Minimum [Member] Actient Pharmaceuticals, LLC [Member] Sales of ten to twenty million [Member]	Apr. 20, 2011 Maximum [Member] Actient Pharmaceuticals, LLC [Member] Sales of ten to twenty million [Member]
Net selling price, percent				30.00%
Increase (decrease) to revenue, adjustments				$ 159,000	$ 220,000	$ 320,000
License fees portion of net sales, percent				20.00%
Payment threshold chievements			350,000	1,400,000			150,000	100,000
Deferred revenue, revenue recognized				0	0	265,168
Proceeds from sale of assets	3,100,000			0	0	15,000,000						3,100,000
Gain on sale of STRIANT		(2,500,000)		0	2,533,127	0								2,500,000
Royalty payment threshold on net sales									0						0			0
Royalty payment threshold tier															$ 10,000,000		$ 20,000,000		$ 10,000,000	$ 20,000,000
Royalty revenue percentage										(0.07)	(0.10)					0.07	0.10
Royalty revenue reduction percentage due to prodcut launch	(0.50)												0.50
Royalty term																		10 years